GSK-3β inhibition promotes cell death, apoptosis, and in vivo tumor growth delay in neuroblastoma Neuro-2A cell line

Journal of Neuro-Oncology

Volumn 104, Issue 1, 2011, Pages 145-153

  Dickey, Amy ^a   Schleicher, Stephen ^a   Leahy, Kathleen ^b   Hu, Rong ^b   Hallahan, Dennis ^b,c   Thotala, Dinesh Kumar ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Cancer therapy; Glycogen synthase kinase 3 beta; Neuroblastoma

Indexed keywords

2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; GLYCOGEN SYNTHASE KINASE 3BETA; LIPOCORTIN 5;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL ASSAY; CELL CLONE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN NEURO 2A; CELL SURVIVAL; CONTROLLED STUDY; DRUG TARGETING; ENZYME INHIBITION; FLOW CYTOMETRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; TUMOR MODEL;

AMINOPHENOLS; ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLORIMETRY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALEIMIDES; MICE; NEUROBLASTOMA; RNA, SMALL INTERFERING; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR STEM CELL ASSAY; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 80052724290     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0491-3     Document Type: Article

References (27)

1. B De Bernardi B Nicolas L Boni P Indolfi M Carli L Cordero Di Montezemolo A Donfrancesco A Pession M Provenzi A di Cataldo A Rizzo GP Tonini S Dallorso M Conte C Gambini A Garaventa F Bonetti A Zanazzo P D'Angelo P Bruzzi 2003 Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma J Clin Oncol 21 1592 1601 12697885 10.1200/JCO.2003.05.191 (Pubitemid 46594114)
2. KK Matthay JG Villablanca RC Seeger DO Stram RE Harris NK Ramsay P Swift H Shimada CT Black GM Brodeur RB Gerbing CP Reynolds 1999 Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group N Engl J Med 341 1165 1173 10519894 10.1056/NEJM199910143411601 1:STN:280: DyaK1MvjsFGnsg%3D%3D (Pubitemid 29480654)
3. A Martinez 2008 Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs Med Res Rev 28 773 796 18271054 10.1002/med.20119 1:CAS:528:DC%2BD1cXhtV2qsLvJ
4. RS Jope GV Johnson 2004 The glamour and gloom of glycogen synthase kinase-3 Trends Biochem Sci 29 95 102 15102436 10.1016/j.tibs.2003.12.004 1:CAS:528:DC%2BD2cXhtVOrtro%3D (Pubitemid 38186580)
5. J Luo 2009 Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy Cancer Lett 273 194 200 18606491 10.1016/j.canlet.2008.05. 045 1:CAS:528:DC%2BD1cXhsV2gtbrI
6. GV Rayasam VK Tulasi R Sodhi JA Davis A Ray 2009 Glycogen synthase kinase 3: more than a namesake Br J Pharmacol 156 885 898 19366350 10.1111/j.1476-5381.2008.00085.x 1:CAS:528:DC%2BD1MXlt1Oqsrg%3D
7. L Wang HK Lin YC Hu S Xie L Yang C Chang 2004 Suppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3 beta in prostate cells J Biol Chem 279 32444 32452 15178691 10.1074/jbc.M313963200 1:CAS:528:DC%2BD2cXmtVChsbs%3D (Pubitemid 39014699)
8. A Shakoori A Ougolkov ZW Yu B Zhang MH Modarressi DD Billadeau M Mai Y Takahashi T Minamoto 2005 Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation Biochem Biophys Res Commun 334 1365 1373 16043125 10.1016/j.bbrc.2005.07.041 1:CAS:528: DC%2BD2MXntVOitb0%3D (Pubitemid 41074725)
9. A Shakoori W Mai K Miyashita K Yasumoto Y Takahashi A Ooi K Kawakami T Minamoto 2007 Inhibition of GSK-3 beta activity attenuates proliferation of human colon cancer cells in rodents Cancer Sci 98 1388 1393 17640304 10.1111/j.1349-7006.2007.00545.x 1:CAS:528:DC%2BD2sXhtVaksrrL (Pubitemid 47241761)
10. AV Ougolkov ME Fernandez-Zapico DN Savoy RA Urrutia DD Billadeau 2005 Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells Cancer Res 65 2076 2081 15781615 10.1158/0008-5472.CAN-04-3642 1:CAS:528:DC%2BD2MXisFGgtbg%3D (Pubitemid 40490111)
11. JG Pizarro J Folch JL Esparza J Jordan M Pallas A Camins 2009 A molecular study of pathways involved in the inhibition of cell proliferation in neuroblastoma B65 cells by the GSK-3 inhibitors lithium and SB-415286 J Cell Mol Med 13 3906 3917 18624766 10.1111/j.1582-4934.2008.00389.x
12. Q Cao X Lu YJ Feng 2006 Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells Cell Res 16 671 677 16788573 10.1038/sj.cr.7310078 1:CAS:528:DC%2BD28XmvFalsLc%3D (Pubitemid 44091443)
13. AV Ougolkov ME Fernandez-Zapico VN Bilim TC Smyrk ST Chari DD Billadeau 2006 Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation Clin Cancer Res 12 5074 5081 16951223 10.1158/1078-0432.CCR-06-0196 1:CAS:528:DC%2BD28XovF2gsr4%3D (Pubitemid 44453333)
14. K Miyashita K Kawakami M Nakada W Mai A Shakoori H Fujisawa Y Hayashi J Hamada T Minamoto 2009 Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma Clin Cancer Res 15 887 897 19188159 10.1158/1078-0432.CCR-08-0760 1:CAS:528:DC%2BD1MXht1Onsbw%3D
15. MP Coghlan AA Culbert DAE Cross SL Corcoran JW Yates NJ Pearce OL Rausch GJ Murphy PS Carter L Roxbee Cox D Mills MJ Brown D Haigh RW Ward DG Smith KJ Murray AD Reith JC Holder 2000 Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription Chem Biol 7 793 803 11033082 10.1016/S1074-5521(00)00025-9 1:CAS:528:DC%2BD3cXotVWitrs%3D
16. J Forde T Dale 2007 Glycogen synthase kinase 3: a key regulator of cellular fate Cell Mol Life Sci 64 1930 1944 17530463 10.1007/s00018-007-7045-7 1:CAS:528:DC%2BD2sXptFKht7s%3D (Pubitemid 47094432)
17. A Martinez A Castro I Dorronsoro M Alonso 2002 Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation Med Res Rev 22 373 384 12111750 10.1002/med.10011 1:CAS:528:DC%2BD38Xltlaksbs%3D (Pubitemid 34620473)
18. H Cui B Hu T Li J Ma G Alam WT Gunning HF Ding 2007 Bmi-1 is essential for the tumorigenicity of neuroblastoma cells Am J Pathol 170 1370 1378 17392175 10.2353/ajpath.2007.060754 1:CAS:528:DC%2BD2sXkvFymtrw%3D (Pubitemid 47339343)
19. P Shastry A Basu MS Rajadhyaksha 2001 Neuroblastoma cell lines-a versatile in vitro model in neurobiology Int J Neurosci 108 109 126 11328706 10.3109/00207450108986509 1:STN:280:DC%2BD38%2FivVWnsg%3D%3D (Pubitemid 32832140)
20. A Brown P Jolly H Wei 1998 Genistein modulates neuroblastoma cell proliferation and differentiation through induction of apoptosis and regulation of tyrosine kinase activity and N-myc expression Carcinogenesis 19 991 997 9667736 10.1093/carcin/19.6.991 1:CAS:528:DyaK1cXktlKrurc%3D (Pubitemid 28375393)
21. V Bilim A Ougolkov K Yuuki S Naito H Kawazoe A Muto M Oya D Billadeau T Motoyama Y Tomita 2009 Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma Br J Cancer 101 2005 2014 19920820 10.1038/sj.bjc.6605437 1:CAS:528:DC%2BD1MXhsFaqtr7N
22. M Wensing T van der Weijden R Grol 1998 Implementing guidelines and innovations in general practice: which interventions are effective? Br J Gen Pract 48 991 997 9624774 1:STN:280:DyaK1c3oslyksg%3D%3D (Pubitemid 28064399)
23. M Mazor Y Kawano H Zhu J Waxman RM Kypta 2004 Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth Oncogene 23 7882 7892 15361837 10.1038/sj.onc.1208068 1:CAS:528:DC%2BD2cXotl2ktbc%3D (Pubitemid 39457038)
24. E Beurel RS Jope 2006 The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways Prog Neurobiol 79 173 189 16935409 10.1016/j.pneurobio.2006.07.006 1:CAS:528: DC%2BD28Xptlyqtr4%3D (Pubitemid 44331500)
25. M Sun G Meares L Song RS Jope 2009 XIAP associates with GSK3 and inhibits the promotion of intrinsic apoptotic signaling by GSK3 Cell Signal 21 1857 1865 19698783 10.1016/j.cellsig.2009.08.002 1:CAS:528:DC%2BD1MXht1GgtrvF
26. QL Deveraux N Roy HR Stennicke T Van Arsdale Q Zhou SM Srinivasula ES Alnemri GS Salvesen JC Reed 1998 IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases EMBO J 17 2215 2223 9545235 10.1093/emboj/17.8.2215 1:CAS:528:DyaK1cXivFOmsb8%3D (Pubitemid 28171907)
27. EM Yazlovitskaya E Edwards D Thotala A Fu KL Osusky WO Whetsell Jr B Boone ET Shinohara DE Hallahan 2006 Lithium treatment prevents neurocognitive deficit resulting from cranial irradiation Cancer Res 66 11179 11186 17145862 10.1158/0008-5472.CAN-06-2740 1:CAS:528:DC%2BD28Xht1KnsL7L (Pubitemid 46009945)